Pfizer says Covid-19 vaccine list price could be $130 per dose once government contracts end - Covıd-19 HEAD TOPICS

Pfizer says Covid-19 vaccine list price could be $130 per dose once government contracts end

10/22/2022 6:46:00 PM

Pfizer says Covid-19 vaccine list price could be $130 per dose once government contracts end

Pfizer-Vaccine Price Covıd-19

Source

ABC7 Eyewitness News

Pfizer says Covid-19 vaccine list price could be $130 per dose once government contracts end Drugmaker Pfizer said Friday that as government contracts come to an end, possibly by early next year, its Covid-19 vaccine will be sold for $110 to $130 per dose. This is the "commercial list price," but the company says it does not anticipate that most people will have to pay out of pocket. It also pointed to its patient assistance program, which helps people without insurance get vaccines.For now, Covid-19 vaccines are still available for free. Pfizer says it anticipates that the Covid-19 vaccine pricing could come into play when the distribution and reimbursement of vaccines transition from government contracts to the traditional health-care system, as early as the first quarter of 2023. Read more:
ABC7 Eyewitness News » Pfizer Targets Covid Vaccine Price of at Least $110 a Dose 'Daylight Robbery': Pfizer Condemned for Hiking US Covid Vaccine Price by 10,000% Above Cost Pfizer COVID vaccine price hike seen giving revenue boost for years Pfizer will start charging $110-$130 a dose for COVID vaccines next year

High school senior Bella Rasmussen becomes first girl to score two touchdowns in one game

Bella Rasmussen, an 18-year-old running back for Laguna Beach (California) High School, became the first girl to score two touchdowns in a game. Read more >> Pfizer Targets Covid Vaccine Price of at Least $110 a DosePfizer said it expects to price its Covid-19 vaccine at $110 to $130 a dose for adults when the U.S. government stops purchases Talk about deterrence. I'm interested in how much Novavax will be. They have been working on a new strain of Covid? Because this “vaccine” is worthless. 'Daylight Robbery': Pfizer Condemned for Hiking US Covid Vaccine Price by 10,000% Above Cost\u0022While health workers and the vulnerable continue to go unvaccinated in developing countries, Pfizer is shamelessly fleecing the public for ever-greater sums of money,\u0022 said one campaigner. peoplesvaccine PLUTOCRACY Government controlled by a wealthy ruling class who rig government policy to benefit corporate intrests KLEPTOCRACY PUBLICLY FUNDED PRIVATE PATENTS US Taxpayers — Fund the Research & Development Private oligopolies retain the patents peoplesvaccine PLUTOCRACY Government controlled by a wealthy ruling class who rig government policy to benefit corporate intrests KLEPTOCRACY PUBLICLY FUNDED PRIVATE PATENTS US Taxpayers — Fund the Research & Development Private oligopolies retain the patents Pfizer COVID vaccine price hike seen giving revenue boost for yearsPfizer's plan to as much as quadruple current U.S. prices for its COVID-19 vaccines going forward could spur revenue for years, analysts said. Pfizer will start charging $110-$130 a dose for COVID vaccines next yearPfizer plans to charge $110 to $130 per dose for its COVID-19 vaccine once government purchases end next year. Americans are enthusiastic about being literal property of big pharmaceutical companies and paypigs to their government. This is the end times. Phizer needs to adopt a Costco style return policy And in Australia, we'll still be paying nothing. America needs a revolution. Pfizer reportedly plans to charge up to $130 for COVID-19 vaccinePfizer said it would charge between $110 and $130 for its mRNA vaccine after the government stops paying for them. That will happen once the public health emergency put in place at the start of the COVID-19 pandemic is ended. What “protection” exactly? 🤦‍🤦‍ But it doesn't work A sucker is born every minute. Pfizer says COVID-19 vaccine will cost $110-$130 per dosePfizer said the commercial pricing for adult COVID-19 vaccine doses could start in early 2023, depending on when the U.S. government phases out its program of buying the shots. FOX13 🤣🤣🤣 Even more reason to tell them to F off with their new product. Let’s see how many of the pro-vaxxers get it this year 😂😂 This price model comes down to increased distribution costs as well as an expected shift from multidose vials to single-dose ones.The drugmaker laid out a potential price as it prepares to sell the shot commercially, perhaps early next year Pfizer said the earliest there could be a commercial rollout would be early next year.the nation's free coronavirus vaccine program as pandemic response funding runs dry.(NVAX. This is the "commercial list price," but the company says it does not anticipate that most people will have to pay out of pocket. It also pointed to its patient assistance program, which helps people without insurance get vaccines. Hopkins Oct. For now, Covid-19 vaccines are still available for free." The outlet noted that Lukin did not say whether the company will make any accommodations for the tens of millions of people in the U. Pfizer says it anticipates that the Covid-19 vaccine pricing could come into play when the distribution and reimbursement of vaccines transition from government contracts to the traditional health-care system, as early as the first quarter of 2023. gave some details about its plans to sell the Covid-19 vaccine it developed with BioNTech SE on the commercial market in the U. An analysis published by the Kaiser Family Foundation this week said that without additional funding or protections, the commercialization of Covid-19 preventative and countermeasures would create access barriers for vaccines, tests and therapeutics -- especially for the uninsured and underinsured. So far, the U. Two key changes will lead to commercialization: the end of the US government's public health emergency declaration and the depletion of federally purchased supply., saying it expects to price the shot at $110 to $130 per dose for adults. The People's Vaccine Alliance said in a statement Friday that Pfizer's planned price hike would amount to a 10,000% markup above the cost of producing the vaccine, which is to be as low as $1. Each change creates its own challenges and, taken together, "may amplify access challenges," the analysis says. Neither change has come to pass; the public health emergency declaration was renewed last week for another 90 days. Continue reading your article with a WSJ membership. But Congress has yet to act on the Biden administration's request for billions more in funding to ensure a steady and accessible supply of Covid-19 countermeasures.S. A large portion of the government's request for further Covid-19 funding is a "critical request" for resources to support development of new vaccines and treatments that can withstand future variants of the coronavirus, said Dawn O'Connell, assistant secretary for preparedness and response within the US Department of Health and Human Services. In the first seven weeks of the 2021 revaccination campaign, over 27 million people received their third shot even though only older and immunocompromised people were eligible at that point. "That would get us out of the boom-bust cycle surge in cases," she said at a news briefing Wednesday hosted by KFF. The goal is to avoid a situation like last winter when there was a test shortage due to lack of anticipation for the Delta variant, said Jen Kates, senior vice president and director of global health & HIV policy with KFF."This latest obscene price hike is truly a mask-off moment for one of the great profiteers of this pandemic. Another portion of the funding would go toward protecting the uninsured and ensuring universal access to Covid-19 countermeasures, O'Connell said. According to the KFF analysis, once the measures are commercialized, uninsured adults would lose access to free vaccines. But treatments and tests would face the "most acute" challenges, with cost sharing that would affect how much of the cost would be covered by insurance. "This is daylight robbery," Kosgei said of the coming price increase. Transitioning to commercialization was always part of the plan, O'Connell said. It's the way other health conditions are approached in the US. "But the process is complex," she said."Right now, people in developing countries are dying without access to Paxlovid, an antiviral Covid-19 treatment for which Pfizer is charging hundreds of dollars per course. "Regardless of whether we were going to get Covid funding, we were eventually going to have to make this transition at some point. Part of the Covid request makes this a little less bumpy. " The-CNN-Wire ." Related Content.